MAP2K2 mutation
|
Melanoma
|
MAP2K2 mutation
|
Melanoma
|
CTLA4 inhibitor Sensitive: C3 – Early Trials
|
CTLA4 inhibitor Sensitive: C3 – Early Trials
|
MAP2K2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
MAP2K2 mutation
|
Pancreatic Ductal Adenocarcinoma
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
avelumab + binimetinib Sensitive: C3 – Early Trials
|
MAP2K2 mutation
|
Melanoma
|
MAP2K2 mutation
|
Melanoma
|
dabrafenib Resistant: D – Preclinical
|
dabrafenib Resistant: D – Preclinical
|
MAP2K2 mutation
|
Melanoma
|
MAP2K2 mutation
|
Melanoma
|
trametinib Resistant: D – Preclinical
|
trametinib Resistant: D – Preclinical
|